US2017087172A1PendingUtilityA1

Sodium glucose co-transporter inhibitors and methods of their use

57
Assignee: LEXICON PHARMACEUTICALS INCPriority: Sep 29, 2006Filed: May 16, 2016Published: Mar 30, 2017
Est. expirySep 29, 2026(~0.2 yrs left)· nominal 20-yr term from priority
Inventors:Bryce A. HarrisonSpencer David KimballRoss MabonDavid Brent Rawlins
A61P 9/12A61P 43/00A61P 3/06A61P 3/10A61P 9/00A61P 5/50A61P 9/10A61P 3/00A61P 3/04A61P 13/00C07H 15/14C07D 211/46C07D 309/10A61K 31/7032C07H 7/04C07D 407/12A61K 31/7028C07D 335/02A61K 31/35C07D 291/06A61K 31/351
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed.

Claims

exact text as granted — not AI-modified
1 - 31 . (canceled) 
     
     
         32 . A method of reducing blood glucose levels in a patient, which comprises administering to a patient in need thereof a therapeutically effective amount of (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-methylsulfanyl-tetrahydro-pyran-3,4,5-triol: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.